AG1295 is a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine kinase; it inhibits PDGFR autophosphorylation (IC50: 0.3–0.5 μM in membrane assays; 0.5–1 μM in Swiss 3T3 cells) without affecting EGF receptor autophosphorylation; it suppresses PDGF-AA- or PDGF-BB-stimulated rabbit conjunctival fibroblast cell growth in vitro; it reduces neointimal formation in aortic allograft vasculopathy by inhibiting PDGFR-beta-triggered tyrosine phosphorylation; it attenuates interstitial fibrosis in rat kidney after unilateral ureteral obstruction, as evidenced by reduced Sirius-Red-stained area, decreased macrophage infiltration, reduced ED-A+ fibronectin deposition, and fewer alpha-smooth muscle actin-positive cells.